China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...
With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback